Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | FABP5 | Q01469 | 3/20 | 0.41 |
| ▸ | FABP7 | O15540 | 2/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 5/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30089351 | 1.00 | POLB (0.50) | POLBFABP5FABP7FKBP1AKMT2A | |
| SCHEMBL2678864 | 0.87 | POLB (0.61) | POLBFKBP1APSEN1PSEN2APH1B | |
| SCHEMBL7433978 | 0.87 | POLB (0.61) | POLBFKBP1APSEN1PSEN2APH1B | |
| SCHEMBL23485199 | 0.87 | POLB (0.61) | POLBFKBP1APSEN1PSEN2APH1B | |
| SCHEMBL30564487 | 0.87 | POLB (0.61) | POLBFKBP1APSEN1PSEN2APH1B | |
| SCHEMBL1335555 | 0.86 | FABP5 (0.46) | POLBFABP5FABP7KMT2AEPHX2 | |
| SCHEMBL1000852 | 0.86 | FABP5 (0.46) | POLBFABP5FABP7KMT2AEPHX2 | |
| SCHEMBL4612189 | 0.86 | FABP5 (0.46) | POLBFABP5FABP7KMT2AEPHX2 | |
| SCHEMBL1336708 | 0.86 | FABP5 (0.46) | POLBFABP5FABP7KMT2AEPHX2 | |
| SCHEMBL31689008 | 0.86 | FABP5 (0.46) | POLBFABP5FABP7KMT2AEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-7807678-B2 | Peptidomimetics of biologically active metallopeptides | PALATIN TECHNOLOGIES, INC. (US) | 2010-10-05 | — | — | US | disclosed |
| US-7601753-B2 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2009-10-13 | — | — | US | disclosed |
| US-20070155670-A1 | Pyrrolidine Melanocortin-Specific Compounds | PALATIN TECHNOLOGIES, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-7189755-B2 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2007-03-13 | — | — | US | disclosed |
| EP-1425029-A4 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES | PALATIN TECHNOLOGIES INC (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20040171520-A1 | Peptidomimetics of biologically active metallopeptides | PALATIN TECHNOLOGIES, INC. | 2004-09-02 | — | — | US | disclosed |
| US-20040167201-A1 | Pyrrolidine melanocortin-specific compounds | PALATIN TECHNOLOGIES, INC. (US) | 2004-08-26 | — | — | US | disclosed |
| EP-1425029-A1 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES | Palatin Technologies, Inc. (US) | 2004-06-09 | — | — | EP | disclosed |
| WO-2003013571-A1 | PEPTIDOMIMETICS OF BIOLOGICALLY ACTIVE METALLOPEPTIDES | PALATIN TECHNOLOGIES, INC. (US) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167201-A1 | Pyrrolidine melanocortin-specific compounds | MC3R, MC1R, MC5R | POLB 2561/4885FABP5 3308/4885FABP7 1618/4885 |
| US-20040171520-A1 | Peptidomimetics of biologically active metallopeptides | MC1R, MC4R, MC5R | POLB 4167/4885FABP5 1044/4885FABP7 1213/4885 |
| US-20070155670-A1 | Pyrrolidine Melanocortin-Specific Compounds | MC3R, MC1R, MC5R | POLB 3019/4885FABP5 3849/4885FABP7 1613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.